Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Surgical Case Reports|July 16, 2024
Larotrectinib efficacy for liver metastases in papillary thyroid carcinoma patient harboring SQSTM1-NTRK1 fusionHaruhiko Yamazaki, Makoto Sugimori, Aya Saito
World Journal of Surgery|March 15, 2023
Migration of Risk Classification Between the JAES Versus ATA guidelines for Papillary Thyroid CarcinomaHaruhiko Yamazaki, Katsuhiko Masudo, Yasushi Rino
Endocrine|July 28, 2024
Prognostic significance of metastatic lymph node size and extra-nodal extension in papillary thyroid carcinoma according to the 9th edition of general rules for the description of thyroid cancer risk stratification: a single center validation studyHaruhiko Yamazaki, Soji Toda, Rika Sasaki, et al.
International Cancer Conference Journal|April 3, 2026
A case of poorly differentiated thyroid carcinoma harboring an <i>SMARCB1</i> mutationRika Sasaki, Haruhiko Yamazaki, Eita Kumagai, et al.
Endocrinology, Diabetes & Metabolism Case Reports|December 19, 2024
Thyroid metastasis from ovarian clear cell carcinomaRika Sasaki, Haruhiko Yamazaki, Eita Kumagai, et al.
Endocrine|February 26, 2024
Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in JapanHaruhiko Yamazaki, Chikara Kunisaki, Makoto Sugimori, et al.
Endocrine|September 7, 2022
Prognostic significance of lung metastasis-related finding in lenvatinib treatment for differentiated thyroid cancerHaruhiko Yamazaki, Hiroyuki Iwasaki, Katsuhiko Masudo, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2025
Tumor response and thyroglobulin change in differentiated thyroid carcinoma treated with dabrafenib plus trametinibHaruhiko Yamazaki, Nobuyasu Suganuma, Mei Kadoya, et al.
Endocrine Journal|May 13, 2026
Efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated advanced thyroid carcinoma: Real world experience in 37 patientsHaruhiko Yamazaki, Nobuyasu Suganuma, Mei Kadoya, et al.
Oncology Letters|December 15, 2018
Lenvatinib as a novel treatment for anaplastic thyroid cancer: A retrospective studyHiroyuki Iwasaki, Haruhiko Yamazaki, Hirotaka Takasaki, et al.
Pageof 5